Royalty Pharma PLC $RPRX Shares Purchased by Cookson Peirce & Co. Inc.

Cookson Peirce & Co. Inc. boosted its position in shares of Royalty Pharma PLC (NASDAQ:RPRX) by 55.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 34,263 shares of the biopharmaceutical company’s stock after purchasing an additional 12,171 shares during the period. Cookson Peirce & Co. Inc.’s holdings in Royalty Pharma were worth $1,234,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. M&T Bank Corp raised its stake in Royalty Pharma by 23.4% during the first quarter. M&T Bank Corp now owns 28,967 shares of the biopharmaceutical company’s stock worth $902,000 after purchasing an additional 5,500 shares during the period. Asset Management One Co. Ltd. raised its stake in shares of Royalty Pharma by 8.0% in the 1st quarter. Asset Management One Co. Ltd. now owns 164,931 shares of the biopharmaceutical company’s stock valued at $5,134,000 after acquiring an additional 12,148 shares during the period. Amalgamated Bank raised its stake in shares of Royalty Pharma by 4.4% in the 1st quarter. Amalgamated Bank now owns 20,423 shares of the biopharmaceutical company’s stock valued at $636,000 after acquiring an additional 866 shares during the period. Nordea Investment Management AB raised its stake in shares of Royalty Pharma by 603.9% in the 2nd quarter. Nordea Investment Management AB now owns 655,995 shares of the biopharmaceutical company’s stock valued at $23,701,000 after acquiring an additional 562,799 shares during the period. Finally, KBC Group NV grew its holdings in shares of Royalty Pharma by 43.0% in the first quarter. KBC Group NV now owns 59,405 shares of the biopharmaceutical company’s stock valued at $1,849,000 after purchasing an additional 17,851 shares in the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Royalty Pharma from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Morgan Stanley lowered their price target on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Citigroup boosted their price target on shares of Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, July 22nd. Wall Street Zen cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a report on Saturday, September 13th. Finally, The Goldman Sachs Group assumed coverage on shares of Royalty Pharma in a report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $46.00.

Royalty Pharma Stock Down 1.7%

Shares of Royalty Pharma stock opened at $36.84 on Thursday. The company has a market cap of $21.48 billion, a P/E ratio of 21.29, a PEG ratio of 2.06 and a beta of 0.60. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.26 and a current ratio of 1.26. Royalty Pharma PLC has a one year low of $24.05 and a one year high of $38.00. The firm has a fifty day moving average of $36.10 and a two-hundred day moving average of $34.91.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. The business had revenue of $578.67 million during the quarter, compared to the consensus estimate of $750.06 million. Royalty Pharma had a net margin of 44.23% and a return on equity of 25.54%. On average, analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Friday, November 14th. Royalty Pharma’s dividend payout ratio is presently 50.87%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.